BioSpace News Archive

The latest market analysis report published by Reports and Data, titled ‘Global Dupuytren’s Disease Treatment Market – Forecast to 2030,’ thoroughly examines the Dupuytren’s Disease Treatment industry to provide essential data & information for the targeted readers.

The latest market analysis report published by Reports and Data, titled ‘Global Hydrocephalus Treatment Market – Forecast to 2030,’ thoroughly examines the Hydrocephalus Treatment industry to provide essential data & information for the targeted readers.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that an ongoing phase II study of paxalisib, an investigational drug for the treatment of diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), sponsored by the Pacific Pediatric Neuro-Oncology Consortium (PNOC).

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its third-quarter 2022 financial results on Wednesday, Nov. 2, 2022.

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced that the Company will present on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the 27th International Hybrid Annual Congress of the World Muscle Society (WMS).

ICON plc, (NASDAQ: ICLR) today announces that it has been selected by the US Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the Department of Health and Human Services (HHS), to execute an anthrax vaccine clinical trial.

Senseonics Holdings, Inc., a medical technology company focused on the design and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes, announced plans to participate in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Juno Diagnostics, a company focused on bringing vital health information to patients by improving access, affordability and transparency, announced the appointment of Todd Whitson as Executive Vice President, Global Business Development and Commercial Operations.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2022 financial results on Friday November 4, 2022, prior to market open.

Caraway Therapeutics today announced that the Company will be presenting new data at The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference, taking place October 13, 2022, in New York, New York.